These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31386039)

  • 1.
    Skorupan N; Ranjan S; Mehta S; Yankulina O; Nenortas N; Grossman S; Ye X; Holdhoff M
    Neurooncol Pract; 2019 Jul; 6(4):321-326. PubMed ID: 31386039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors.
    Arnold LM; Hoshina Y; Lee H; Colman H; Mendez J
    J Neurooncol; 2024 Mar; 167(1):211-217. PubMed ID: 38363493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
    Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
    Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of Pneumocystis jirovecii prophylaxis use among pediatric solid organ transplant providers.
    Paulsen G; Michaels MG; Danziger-Isakov L; Dipchand AI; Green M; McCulloch M
    Pediatr Transplant; 2020 Feb; 24(1):e13609. PubMed ID: 31713958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
    Sidhu VK; Foisy MM; Hughes CA
    Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
    Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
    J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
    Avino LJ; Naylor SM; Roecker AM
    Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
    Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
    Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation- a patient and physician survey.
    Beltran-Bless AA; Alshamsan B; Jia J; Lo V; Climans S; Nicholas G; Ng TL
    J Neurooncol; 2024 Sep; 169(3):625-632. PubMed ID: 39105955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers.
    Okafor PN; Wasan SK; Farraye FA
    Inflamm Bowel Dis; 2013; 19(4):812-7. PubMed ID: 23435401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
    Haeusler GM; Slavin MA; Seymour JF; Lingaratnam S; Teh BW; Tam CS; Thursky KA; Worth LJ
    Eur J Haematol; 2013 Aug; 91(2):157-63. PubMed ID: 23668894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.
    Ghembaza A; Vautier M; Cacoub P; Pourcher V; Saadoun D
    Chest; 2020 Dec; 158(6):2323-2332. PubMed ID: 32502592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
    Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
    Gupta D; Zachariah A; Roppelt H; Patel AM; Gruber BL
    J Clin Rheumatol; 2008 Oct; 14(5):267-72. PubMed ID: 18679133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant.
    Sweiss K; Anderson J; Wirth S; Oh A; Quigley JG; Khan I; Saraf S; Mactal-Haaf C; Rondelli D; Patel P
    Bone Marrow Transplant; 2018 Mar; 53(3):300-306. PubMed ID: 29269796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation.
    Lipsitt A; Hijano DR; Ferrolino JA; Dallas R; Sharma A; Maron G
    Pediatr Blood Cancer; 2024 Oct; 71(10):e31201. PubMed ID: 39010649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Absolute CD4 Count and Percentage Discordance on Pneumocystis Jirovecii Pneumonia Prophylaxis in HIV-Infected Patients.
    Anyimadu H; Pingili C; Sivapalan V; Hirsch-Moverman Y; Mannheimer S
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218759199. PubMed ID: 29534652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.